Shepherd Financial Partners LLC Invests $825,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Shepherd Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,741 shares of the biopharmaceutical company’s stock, valued at approximately $825,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. iA Global Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares in the last quarter. SCS Capital Management LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $34,784,000. Hussman Strategic Advisors Inc. purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $2,505,000. Hsbc Holdings PLC raised its stake in Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares during the period. Finally, Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $243,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Chardan Capital reiterated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Bank of America reduced their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Oppenheimer decreased their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Truist Financial lowered their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. dropped their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $386.62.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Up 6.1%

Alnylam Pharmaceuticals stock opened at $242.61 on Thursday. The company’s fifty day simple moving average is $269.15 and its 200-day simple moving average is $298.51. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The stock has a market cap of $32.46 billion, a P/E ratio of 45.09 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the business posted ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.